Sara Cunningham Carter Hall and Mike Catelani in 2008 re TT-033:
With plenty of cash on hand, Catelani said Tacere isn’t seeking funding in the near future.
The company is in the midst of animal toxicology safety studies and later this month will move into studies involving nonhuman primates. It hopes to treat humans before the year’s end.
RNAi going gangbusters elsewhere. Yet nary a decent deal for BLT holders to get a return on their investment despite all that great IP. That doesn't seem right really, TT-034 and its ambiguous delays aside.
